• Enhancing Proteasome Assay Rigor: (R)-MG132 (SKU C3348) in F

  2026-07-06

  For biomedical researchers seeking stringent controls in cell-based assays, (R)-MG132 (SKU C3348) offers a validated, low-cytotoxicity negative control for proteasome inhibition studies. This article dissects real-world lab scenarios, demonstrating how (R)-MG132 elevates data clarity, reproducibility, and workflow precision in ubiquitin-proteasome system research.

• Cinoxacin: In Vitro Antibacterial Spectrum and Resistance Pa

  2026-07-06

  The reference study systematically characterizes Cinoxacin, a synthetic quinolone antibiotic, by mapping its in vitro antibacterial activity and resistance dynamics against a diverse set of Gram-negative bacilli. Key findings include robust activity against Escherichia coli and related pathogens, a close correlation between MICs and disk diffusion results, and clear documentation of rapid resistance emergence—highlighting both the strengths and limitations for urinary tract infection research.

• Gamithromycin (ML-1709460): PK/PD, Efficacy & Respiratory Ap

  2026-07-05

  Gamithromycin (ML-1709460) is a 15-membered semi-synthetic macrolide antibiotic with proven efficacy against key respiratory pathogens in cattle and pigs. Its pharmacokinetics favor high lung tissue penetration and enhanced potency in serum. The product is validated for the treatment of bovine respiratory disease and Glässer’s disease in pigs, with a robust evidence base supporting its use.

• S-nitrosylation Regulates STOP1/STAR1 in Arabidopsis Al Resi

  2026-07-04

  This study reveals how nitric oxide-mediated S-nitrosylation differentially modulates the stability of STOP1 and STAR1, key regulators of aluminum resistance in Arabidopsis. The findings advance understanding of how plants coordinate external and internal detoxification mechanisms to adapt to acidic soils, with practical implications for improving plant resilience.

• Hydrazide-Based VEGFR-2 Inhibitors: Advances in Antiangiogen

  2026-07-03

  This study reports the design and evaluation of 53 hydrazide-based VEGFR-2 inhibitors, highlighting SA7 as a promising candidate with potent antiangiogenic and antiproliferative effects. The findings underscore the importance of targeting VEGFR-2 in tumor angiogenesis and provide a comparative benchmark with established agents like sorafenib.

• Birinapant (TL32711): Bridging Apoptosis Mechanisms to Trans

  2026-07-03

  Explore how Birinapant (TL32711) advances biomarker-driven, mechanism-based apoptosis research and translational strategies in oncology. This article integrates mechanistic insights, experimental guidance, and strategic recommendations for researchers seeking to overcome chemoradiotherapy resistance, referencing recent breakthroughs in MDM1-mediated apoptosis and drawing on the latest evidence to contextualize Birinapant’s unique value in cancer biology workflows.

• (S)-(+)-Ibuprofen: COX Inhibition and Research Benchmarks

  2026-07-02

  (S)-(+)-Ibuprofen is a potent COX inhibitor used in inflammation pathway research and pain mechanism studies. Its selectivity, tolerability, and defined bioactivity parameters make it optimal for in vitro and in vivo protocols.

• Pepstatin A (SKU A2571): Data-Driven Solutions for Aspartic

  2026-07-02

  This article delivers a scenario-driven, evidence-based guide for biomedical researchers, emphasizing how Pepstatin A (SKU A2571) addresses real laboratory challenges in cell viability, viral protein processing, and osteoclast differentiation inhibition. By integrating scientific references and protocol recommendations, it highlights the reproducibility and specificity of Pepstatin A, positioning it as a gold-standard reagent for sensitive and reliable aspartic protease inhibition.

• Canagliflozin: SGLT2 Inhibitor Workflows for Renal Research

  2026-07-01

  Canagliflozin stands out as a selective SGLT2 inhibitor that enables researchers to dissect renal glucose reabsorption and mitochondrial bioenergetics in metabolic disease models. This article spotlights advanced experimental workflows, troubleshooting strategies, and key innovations from recent studies, transforming diabetes and kidney research.

• MSC Spheroid EVs Enhance 3D-Printed Liver Lobule Therapy for

  2026-07-01

  This study demonstrates that extracellular vesicles (EVs) derived from mesenchymal stromal/stem cell (MSC) spheroids significantly enhance the therapeutic efficacy of 3D-printed vascularized artificial liver lobules in acute liver failure (ALF). By integrating proteomic and functional analyses, the authors reveal mechanisms for improved hepatic differentiation and tissue integration, offering new translational strategies for bioengineered liver support.

• Talabostat Mesylate (PT-100): Reliable DPP4 & FAP Inhibition

  2026-06-30

  This article empowers biomedical researchers with scenario-driven guidance for deploying Talabostat mesylate (SKU B3941) in cell viability and tumor microenvironment assays. Drawing on peer-reviewed evidence and practical protocols, it demonstrates how this specific DPP4 and FAP inhibitor from APExBIO ensures reproducibility, precision, and workflow compatibility.

• Cy5-UTP (Cyanine 5-UTP): Illuminating RNA Delivery & Brain T

  2026-06-30

  Discover how Cy5-UTP (Cyanine 5-uridine triphosphate) advances RNA labeling for brain-targeted research. This deep dive explores its unique value in visualizing RNA delivery, assay optimization, and next-generation neuroscience applications.

• PAD4-IN-2 TFA: Precision PAD4 Inhibition for Tumor Research

  2026-06-29

  PAD4-IN-2 TFA offers tumor-selective PAD4 inhibition via meta-phenylboronic acid modification, enabling researchers to dissect histone H3 citrullination and NET formation in cancer models. Its robust antitumor efficacy, high selectivity, and favorable safety profile make it a transformative tool for tumor microenvironment and metastasis studies.

• Latrunculin B Inhibitor: Precise Disruption of Actin Dynamic

  2026-06-29

  Latrunculin B is a cell-permeable inhibitor of actin polymerization, used for transient disruption of the actin cytoskeleton in cellular studies. Its direct 1:1 binding to G-actin enables precise control of actin filament assembly inhibition, though its effects are rapidly reversible in serum-containing media. This article details the mechanisms, evidence, and workflow integration for Latrunculin B, with attention to its validated limits.

• Gastrin I Peptide: Precision Tools for Gastric Acid Pathway

  2026-06-28

  Harness the specificity of human Gastrin I peptide for advanced modeling of gastric acid secretion and CCK2 receptor signaling. This guide delivers actionable workflows, troubleshooting insights, and practical enhancements for gastrointestinal physiology studies, especially in hiPSC-derived organoid systems.

448 records 12/30 page Previous Next First page 上5页 1112131415 下5页 Last page